ArticleThe Lancet regional health. Western Pacific2024
Using routinely collected data to determine care cascades of hypertension and type-2 diabetes management in China: a cross-sectional study.
Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and treatment and control rates of hypertension among Chinese adults from 2016 to 2022: a meta-analysis.BMC public health · 2026Pooled it
- Inequality in prevalence of unmedicated hypertension or diabetes among older Filipinos: analysis of nationally representative survey data.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- The economic impact of national essential public health service package for hypertension and type-2 diabetes: a retrospective province-wide study in China.Archives of public health = Archives belges de sante publique · 2026Article
- Chronic kidney disease burden from 1990 to 2023 in China: national and provincial insights from the Global Burden of Diseases study 2023.The Lancet regional health. Western Pacific · 2026Article
- Observational
- Proactive health behaviour intervention strategies for older T2DM patients with multimorbidity: protocol for a cluster randomised controlled trial with hybrid type 2 effectiveness-implementation design.BMC primary care · 2026Article
- Using the Behaviour Change Wheel framework to develop an integrated intervention for diabetes and hypertension co-management in China: a case report.BMC global and public health · 2025Review
- Measurement of catastrophic health expenditures in households with essential hypertension and type 2 diabetes mellitus in cold regions of China.Health economics review · 2025Article
- Quality safety and disparity of an AI chatbot in managing chronic diseases: simulated patient experiments.NPJ digital medicine · 2025Article
- Development and Internal Validation of a Clinical Imaging-Based Stroke Prediction Model in a Community Cohort.Journal of the American Heart Association · 2025Article
- Barriers and Facilitators to Implementing Food is Medicine for the Management of Type 2 Diabetes in China.Journal of general internal medicine · 2025Article
- Unveiling pathways to enhance hypertension and diabetes care in rural China: a mixed methods study using the care cascade model.The Lancet regional health. Western Pacific · 2025Article
- Using primary and routinely collected data to determine prevalence and patterns of multimorbidity in rural China: a representative cross-sectional study of 6474 Chinese adults.The Lancet regional health. Western Pacific · 2025Article
- Complication development trajectories for patients with type 2 diabetes mellitus: evidence from a five-million retrospective cohort study.Frontiers in health services · 2025Article
- Article
- Missed opportunities for hypertension screening of older people in the Philippines: cross-sectional analysis of nationally representative individual-level data.The Lancet regional health. Western Pacific · 2024Article
- Co-designing interventions to strengthen the primary health care system for the management of hypertension and type 2 diabetes in China.The Lancet regional health. Western Pacific · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China's National Essential Public Health Service Package (NEPHSP) aims to promote health for all at the primary health care level and includes a focus on hypertension and type-2 diabetes mellitus (T2DM). However, there are limited contemporary data to quantify the care cascades of hypertension and T2DM in primary health care. Methods: This cross-sectional study involved individual level linkage of routinely collected data from the NEPHSP, health insurance claims and hospital electronic health records, from four diverse regions in China, including Xiling District (central China), Wenchuan County (western), Acheng District and Jiao District (northern). We first compared numbers of people aged ≥35 with a recorded diagnosis of hypertension and T2DM against expected numbers derived from epidemiological data. We then constructed care cascades to assess the percentages (1) enrolled in the NEPHSP, (2) adherent to the follow-up care of NEPHSP, (3) receiving medication treatment, and (4) having hypertension and/or T2DM controlled. Findings: In the four regions, the total numbers of people aged ≥35 diagnosed of hypertension and T2DM from any data source were 149,176 and 50,828, respectively. This was estimated to be 46.0% (95% confidence interval [CI]: 45.8%-46.2%) and 45.6% (95% CI: 45.3%-45.9%) of the expected totals for hypertension and T2DM, respectively. Among those diagnosed, 65.4% (95% CI: 65.1%-65.6%) with hypertension and 66.1% (95% CI: 65.7%-66.5%) with T2DM were enrolled in the NEPHSP, respectively, in which 54.8% (95% CI: 54.5%-55.2%) with hypertension and 64.7% (95% CI: 64.1%-65.2%) with T2DM were adherent to the required services. Among those enrolled, the overall treatment rates were 70.8% (95% CI: 70.6%-71.1%) for hypertension and 82.2% (95% CI: 81.8%-82.6%) for T2DM. Among those treated, a further 80.9% (95% CI: 80.6%-81.2%) with hypertension and 73.9% (95% CI: 73.3%-74.4%) with T2DM achieved control. These results varied considerably across regions, with the northern sites showing relatively higher enrolment rates while the central site had higher control rates. Interpretation: Detection and control rates for hypertension and T2DM are suboptimal in these four regions of China. Further strategies are needed to improve people's enrolment in and adherence to the NEPHSP and strengthen care delivery processes. Of note, our estimations of the diagnosis rates for each region are based on national level large epidemiological data. The interpretation of these data needs caution due to potential bias caused by regional variations. Funding: This study is funded by National Health and Medical Research Council (NHMRC) Global Alliance for Chronic Diseases funding (APP1169757), and National Natural Science Foundation of China (72074065).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.